The Native Antigen Company, a leading supplier of reagents for research into vaccines and diagnostics for emerging and endemic infectious diseases, has announced the commercial introduction of its novel coronavirus antigens, derived from the COVID-19 strain.
The Native Antigen Company has developed rapid-response manufacturing capabilities to produce reagents for emerging epidemic diseases according to the World Health Organization's R&D Blueprint, which urges the accelerated development of vaccines and the increased availability of accurate and reliable diagnostics for priority emerging infectious diseases.
These antigens have been derived specifically from the newly identified COVID-19 coronavirus using the company’s proprietary mammalian VirtuE expression system. This system is able to introduce proper protein folding and post-translational modifications to recombinant proteins, which are essential for full biological and antigenic activity.
https://thenativeantigencompany.com